Breaking Finance News

A statement released earlier today by Numis about Abzena Plc (LON:ABZA) bumps the target price to 80.00GBX

Having a price of 35.50GBX, Abzena Plc (LON:ABZA) traded 0.00% even on the day. With the last close down 12.44% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the same period. Abzena Plc has recorded a 50-day average of 46.24GBX and a two hundred day average of 41.36GBX. Volume of trade was down over the average, with 10,950 shares of ABZA changing hands under the typical 627,924

Stating a potential upside of 1.25%, Numis upped the price target of Abzena Plc (LON:ABZA) to 80.00GBX

On 8/29/2017, finnCap released a statement on Abzena Plc (LON:ABZA) maintained the target price at 80.00GBX that suggested an upside of 0.93%.

Performance Chart

Abzena Plc (LON:ABZA)

With a total market value of 0 GBX, Abzena Plc has with a one year low of 31.00GBX and a one year high of 66.00GBX .

More About Abzena Plc (LON:ABZA)

Abzena plc is a life sciences company. The Company provides technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It has a global customer base which includes approximately 20 biopharmaceutical companies, as well as large and small biotech companies and academic groups. It offers immunogenicity assessment, which includes EpiScreen, iTope and T Cell Epitope Database (TCED); antibody drug conjugates, which includes ThioBridge linkers; antibody, which includes Composite Human Antibodies and Composite Proteins; optimization of pharmacokinetics, which includes TheraPEG, HiPEG conjugates PEG to poly-histidine motifs and CyPEG, and PolyPEG; cell line development, which includes Composite Human Antibody; process development, Good manufacturing practices (GMP) manufacturing, and small molecules. The Company's Abzena inside includes Composite Human Antibodies and ThioBridge Antibody Drug Conjugates (ADCs).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.